Thomas Ray Miner, DO in Dyersville, IA - Medicare Family Practice

Thomas Ray Miner, DO is a medicare enrolled "Family Medicine" physician in Dyersville, Iowa. He went to Des Moines University Of Osteopathic Medicine And Health Sciences and graduated in 1984 and has 40 years of diverse experience with area of expertise as Family Practice. He is a member of the group practice Central Community Hospital, Medical Associates Clinic Pc and his current practice location is 1121 3rd St Sw, Dyersville, Iowa. You can reach out to his office (for appointments etc.) via phone at (563) 875-2776.

Thomas Ray Miner is licensed to practice in Iowa (license number 02121) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1902850704.

Contact Information

	Thomas Ray Miner, DO
	1121 3rd St Sw, Dyersville, IA 52040-1725
	(563) 875-2776
	(563) 875-7657

Physician's Profile

Full Name	Thomas Ray Miner
Gender	Male
Speciality	Family Practice
Experience	40 Years
Location	1121 3rd St Sw, Dyersville, Iowa
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Thomas Ray Miner attended and graduated from Des Moines University Of Osteopathic Medicine And Health Sciences in 1984

NPI Data:

NPI Number: 1902850704
Provider Enumeration Date: 05/19/2006
Last Update Date: 01/12/2011

Medicare PECOS Information:

PECOS PAC ID: 2668429176
Enrollment ID: I20060321000623

Medical Identifiers

Medical identifiers for Thomas Ray Miner such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1902850704	NPI	-	NPPES
1091983	Medicaid	IA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Q00000X	Family Medicine	02121 (Iowa)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Mercyone Elkader Medical Center	Elkader, IA	Hospital
Mercyone Dyersville Medical Center	Dyersville, IA	Hospital

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Central Community Hospital	1052206372	14
Medical Associates Clinic Pc	3870491228	192

News Archive

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Altheus Therapeutics, announced that it has completed a two dose, double-blind, active-controlled Phase I clinical trial of the safety and tolerability of Zoenasa Rectal Suspension in adult patients with left-sided, or distal, ulcerative colitis.

Tubulin protein is a well-validated cancer drug target

Tubulin, the building-block protein of cellular microtubules, is a well-validated cancer drug target: Disrupting tubulin polymerization affects cytoskeletal function and thus cell division.

IDT's innovative Alt-R CRISPR-Cas9 System improves genome editing potency, reduces cell toxicity

Integrated DNA Technologies, introduces a new approach to CRISPR—its innovative Alt-R CRISPR-Cas9 System, based on the naturally occurring S. pyogenes CRISPR RNA system.

UAB researchers identify possible mechanism of cognition that underlies ASD

Researchers at the University of Alabama at Birmingham have identified a possible mechanism of human cognition that underlies autism spectrum disorders, or ASD.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Thomas Ray Miner allows following entities to bill medicare on his behalf.

Entity Name	Medical Associates Clinic Pc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1457300790 PECOS PAC ID: 3870491228 Enrollment ID: O20031223000311

News Archive

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Tubulin protein is a well-validated cancer drug target

Tubulin, the building-block protein of cellular microtubules, is a well-validated cancer drug target: Disrupting tubulin polymerization affects cytoskeletal function and thus cell division.

IDT's innovative Alt-R CRISPR-Cas9 System improves genome editing potency, reduces cell toxicity

Integrated DNA Technologies, introduces a new approach to CRISPR—its innovative Alt-R CRISPR-Cas9 System, based on the naturally occurring S. pyogenes CRISPR RNA system.

UAB researchers identify possible mechanism of cognition that underlies ASD

Researchers at the University of Alabama at Birmingham have identified a possible mechanism of human cognition that underlies autism spectrum disorders, or ASD.

Entity Name	Central Community Hospital
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1578600961 PECOS PAC ID: 1052206372 Enrollment ID: O20040217000210

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Tubulin protein is a well-validated cancer drug target

Tubulin, the building-block protein of cellular microtubules, is a well-validated cancer drug target: Disrupting tubulin polymerization affects cytoskeletal function and thus cell division.

IDT's innovative Alt-R CRISPR-Cas9 System improves genome editing potency, reduces cell toxicity

Integrated DNA Technologies, introduces a new approach to CRISPR—its innovative Alt-R CRISPR-Cas9 System, based on the naturally occurring S. pyogenes CRISPR RNA system.

UAB researchers identify possible mechanism of cognition that underlies ASD

Researchers at the University of Alabama at Birmingham have identified a possible mechanism of human cognition that underlies autism spectrum disorders, or ASD.

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Thomas Ray Miner is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Thomas Ray Miner, DO 1500 Associates Dr, Dubuque, IA 52002-2201 Ph: (563) 584-4100	Thomas Ray Miner, DO 1121 3rd St Sw, Dyersville, IA 52040-1725 Ph: (563) 875-2776

News Archive

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Tubulin protein is a well-validated cancer drug target

Tubulin, the building-block protein of cellular microtubules, is a well-validated cancer drug target: Disrupting tubulin polymerization affects cytoskeletal function and thus cell division.

IDT's innovative Alt-R CRISPR-Cas9 System improves genome editing potency, reduces cell toxicity

Integrated DNA Technologies, introduces a new approach to CRISPR—its innovative Alt-R CRISPR-Cas9 System, based on the naturally occurring S. pyogenes CRISPR RNA system.

UAB researchers identify possible mechanism of cognition that underlies ASD

Researchers at the University of Alabama at Birmingham have identified a possible mechanism of human cognition that underlies autism spectrum disorders, or ASD.

Family Medicine Doctors in Dyersville, IA

Robert Stanley Tomas, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1121 3rd St Sw, Dyersville, IA 52040 Phone: 563-875-2776 Fax: 563-875-7657
Joseph John Snyder, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1121 3rd St Sw, Dyersville, IA 52040 Phone: 563-875-2776 Fax: 563-875-7657

Thomas Ray Miner, DO - Medicare Family Practice in Dyersville, IA

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medical Facilities Affiliation

Group Practice Association

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Tubulin protein is a well-validated cancer drug target

IDT's innovative Alt-R CRISPR-Cas9 System improves genome editing potency, reduces cell toxicity

UAB researchers identify possible mechanism of cognition that underlies ASD

Medicare Reassignments

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Tubulin protein is a well-validated cancer drug target

IDT's innovative Alt-R CRISPR-Cas9 System improves genome editing potency, reduces cell toxicity

UAB researchers identify possible mechanism of cognition that underlies ASD

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Tubulin protein is a well-validated cancer drug target

IDT's innovative Alt-R CRISPR-Cas9 System improves genome editing potency, reduces cell toxicity

UAB researchers identify possible mechanism of cognition that underlies ASD

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Tubulin protein is a well-validated cancer drug target

IDT's innovative Alt-R CRISPR-Cas9 System improves genome editing potency, reduces cell toxicity

UAB researchers identify possible mechanism of cognition that underlies ASD

Family Medicine Doctors in Dyersville, IA